Abstract
Pelletier JS, Tessema B, Frank S, Westover JB, Brown SM, Capriotti JA. Efficacy of povidone-iodine nasal and oral antiseptic preparations against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Ear, Nose Throat J. September 2020. doi:10.1177/0145561320957237
The authors of this paper have included this notice to alert readers to their similar study published in JAMA Otolaryngology–Head & Neck Surgery, entitled “In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2.” Each article is the result of a distinct experiment with a distinct hypothesis.
This Ear Nose & Throat Journal article demonstrates the ability of nasal and oral solutions of povidone-iodine at various concentrations to inactivate the SARS-CoV-2 virus, with the lowest contact time reported of 60 seconds. The JAMA Otolaryngology–Head & Neck Surgery article addressed the clinically relevant question of minimal duration of contact time of povidone-iodine nasal solution for maximal viral inactivation of SARS-CoV-2. That article demonstrates inactivation at 15 and 30 seconds.
Although similar methodology was utilized, these studies were separate experiments with separate results that addressed separate hypotheses. The information from each study was disseminated rapidly so that otolaryngologists could not only be informed about the efficacy of povidone-iodine but also about necessary contact time. Due to publishing and editing time constraints, the JAMA Otolaryngology–Head & Neck Surgery article was published prior to this Ear, Nose & Throat Journal article. The authors thank readers for their interest in the author’s research regarding this important topic.
The authors have additionally corrected their conflict of interest statement for the article to the following:
Dr Pelletier is a consultant for Veloce BioPharma and reported equity in both Veloce BioPharma and Halodine. Dr Tessema reported personal financial investment in Halodine outside the submitted work and has a patent to multiple drug products pending. Dr Brown reported personal financial investment in Halodine outside the submitted work. Dr Capriotti is the executive director of Veloce BioPharma and reported a patent to multiple related drugs issued and licensed by Veloce BioPharma.